Піоглітазон у лікуванні хворих на цукровий діабет 2-го типу

Автор(и)

  • О. П. Кіхтяк Львівський національний медичний університет імені Данила Галицького, Львів

DOI:

https://doi.org/10.24026/1818-1384.3(40).2012.83693

Ключові слова:

type 2 diabetes mellitus, pioglitazone, insulin resistance, adiponectin, C-peptide

Анотація

Decreasing of insulin level without any changes of C-peptide was observed during treatment with pioglitazone in patients with type 2 diabetes mellitus. This may suggest enhancing of peripheral insulin binding to its receptors. Treatment with pyoglitazone promotes increase in insulin resistance by the following laboratory criteria: ÍbÀ1ñ, fasting insulin and glucose, adiponectin. Elevation of adiponectin level following treatment with pyoglitazone may be the evidence of clinically important affect toward insulin resistance of adipose tissue, as well as on insulin resistance in muscles and vessels.

Біографія автора

О. П. Кіхтяк, Львівський національний медичний університет імені Данила Галицького, Львів

O. Kikhtyak

Посилання

Rodbard Y.W. American Association of Clinical Endocrinologists – medical guidelines for clinical practice for the management of diabetes mellitus / Y.W. Rodbard, L. Blonde, S.S. Braithwaite // Endocrine Practice. – 2007. – Vol. 13, Suppl. 1. – P. 1-68. https://doi.org/10.4158/ep.13.s1.1

Managing type 2 diabetes: going beyond glycemic control / M.W. Stolar, B J. Hoogwerf, S.M. Gorshow [et al.] // J. Manag. Care Pharm. – 2008 – Vol. 14, Suppl. 5B. – P. 2-19. https://doi.org/10.18553/jmcp.2008.14.s5-b.1

Donnelly R. Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes / R. Donnelly // Int. J. Clin. Practice. – 2007. – Vol. 61, № 7. – P. 1160-1169. https://doi.org/10.1111/j.1742-1241.2007.01396.x

Kahn B.B. Obesity and insulin resistance / B.B. Kahn, J.S. Flier // J. Clin. Invest. – 2000. – Vol. 106, № 4. – P. 473-481. https://doi.org/10.1172/jci10842

Olefsky J.M. Treatment of insulin resistance with peroxisome proliferator-activated receptor [gamma] agonists / J.M. Olefsky // J. Clin. Invest. – 2000. – Vol. 106, № 4. – P. 467-472. https://doi.org/10.1172/jci10843

A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications / B. Molavi, N. Rassouli, S. Bagwe, N. Rassouli // Vasc. Health and Risk Management. – 2007. – Vol. 3, № 6. – P. 967-973.

Ланг Т. А. Как описывать статистику в медицине. Аннотированное руководство для авторов, редакторов и рецензентов / Т. А. Ланг, М. Сесик; пер. с англ. под ред. В. П. Леонова. – М.: Практическая медицина, 2011. – 480 с.

Correlation of the leptin: adiponectin ratio with measures of insulin resistance in non-diabetic individuals / F.M. Finucane, J. Luan, N.J. Wareham [et al.] // Diabetologia. – 2009. – Vol. 52, № 11. – P. 2345-2349. https://doi.org/10.1007/s00125-009-1508-3

TNF-α mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations / A.M. Joussen, S. Doehmen, M.L. Le [et al.] // Molec. Vision. – 2009. – Vol. 15. – P. 1418-1428. – Режим доступу до журн.:

http://www.ncbi.nlm.nih.gov/pubmed

Lang K. Leptin and adiponectin: new players in the field of tumor cell and leukocyte migration / K. Lang, J. Ratke // Cell. Commun. Signal. – 2009. – Vol. 7, № 1. – P. 27. https://doi.org/10.1186/1478-811x-7-27

##submission.downloads##

Опубліковано

2012-09-17

Номер

Розділ

Статті